CBLL at a glance
Ceribell, Inc. (CBLL, SEC CIK 1861107) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ceribell, Inc. (CBLL) reported revenue of $89.1 million (up 36.1% from FY2024) and a net loss of $53.4 million. Diluted EPS was -$1.46.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Ceribell, Inc. (CBLL) shares worth $276.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Woo Raymond on October 1, 2026 of 4,887 shares at $24.38 per share.
- In the last 90 days, CBLL insiders reported 0 open-market purchases ($0) and 20 open-market sales ($5.0M) on Form 4, a net sale of $5.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $89.1M
- +36.1% vs prior year
- Insiders · 90 days
- 0 buys · 20 sells
- Net −$5.0M
- 13F holders
- 26 funds
- $276.4M · +1 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New AI compliance risk triggered by generative-AI adoption and vendors’ undisclosed AI use, potentially affecting privacy and data protection
- Most materially updated geopolitical risk from Iran-related Middle East conflict, threatening Strait of Hormuz shipping and logistics costs
- Regulatory risk from Uyghur Forced Labor Prevention Act, potentially prohibiting imports involving Xinjiang forced labor
- Near-term supply-chain risk from reliance on two primary China contract manufacturers and significant China-sourced components
- Financial risk from $39.0 million six-month net loss and $259.4 million accumulated deficit as of June 30, 2026
AI summary of the CBLL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results announced August 10, 2026
- Detailed financial results and management commentary provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $28.1M, up 33%; product revenue $21.2M and subscription revenue $6.9M signal broad adoption
- Gross margin reached 92% versus 88%, supported by Vietnam manufacturing and one-time tariff refunds
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from seven to nine directors, creating two new seats
- Burke and Taylor shifted from Class I to Classes II and III, respectively, balancing three directors per class
Item 5.07: Submission of Matters to a Vote of Security Holders
- Josef Parvizi and Rebecca Robertson elected as Class II directors through 2029
- Director votes included 4,374,728 broker non-votes, limiting participation on those elections
AI summaries of CBLL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CBLL
Don't miss the next CBLL filing
- Alerts as it files. A push when CBLL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CBLL, by share count.
- Ask anything. An AI agent that reads every CBLL filing and answers with sources.
CBLL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Woo Raymond | M | Oct 1, 2026 | 4,864 | - |
| Woo Raymond | M | Oct 1, 2026 | 23 | - |
| Woo Raymond | M | Oct 1, 2026 | 4,864 | $3.65 |
| Woo Raymond | M | Oct 1, 2026 | 23 | $4.70 |
| Woo Raymond | Sell | Oct 1, 2026 | 4,887 | $24.38 |
| Blumberg Scott | M | Sep 15, 2026 | 846 | - |
| Blumberg Scott | M | Sep 15, 2026 | 846 | $9.41 |
| Chao Xingjuan | Sell | Sep 15, 2026 | 20,846 | $25.03 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $65.4M | $89.1M |
| Gross Profit | - | $56.8M | $78.3M |
| Operating Income | - | -$39.7M | -$58.4M |
| Net Income | - | -$40.5M | -$53.4M |
| Gross Margin | - | 86.7% | 87.9% |
| Op. Margin | - | -60.7% | -65.6% |
| Net Margin | - | -61.8% | -60.0% |
| Balance Sheet | |||
| Total Assets | $58.9M | $225.4M | $195.8M |
| Equity | - | $191.2M | $155.3M |
| ROE | - | -21.2% | -34.4% |
| Per Share | |||
| EPS | $-5.56 | $-3.39 | $-1.46 |
| Cash Flow | |||
| Operating CF | - | -$35.0M | -$40.8M |
| CapEx | - | $1.3M | $767K |
Source: XBRL data in Ceribell, Inc. (CBLL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CBLL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $276.4M |
| Q1 2026 | 25 | $244.9M |
| Q4 2025 | 21 | $245.5M |
| Q3 2025 | 18 | $126.1M |
| Q2 2025 | 20 | $190.2M |
| Q1 2025 | 13 | $135.4M |
| Q4 2024 | 14 | $186.8M |
- FMR LLC (Fidelity)+841.0K (+17%)
- Millennium Management+175.2K (+32%)
- BlackRock+122.9K (+7%)
- Franklin Resources+108.8K (+13%)
- D.E. Shaw & Co+64.3K (+76%)
- BNY Mellon−264.3K (-23%)
- Two Sigma Investments−216.2K (-66%)
- Goldman Sachs Group−130.7K (-32%)
- Citadel Advisors LLC−93.4K (-32%)
- Bank of America Corp−82.4K (-26%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 137 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CBLL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 9, 2026 | - | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
CBLL SEC filings: frequently asked questions
Are CBLL insiders buying or selling?
In the last 90 days, Ceribell, Inc. (CBLL) officers, directors and 10% owners reported no open-market purchases and 20 open-market sales worth $5.0 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CBLL stock?
As of June 30, 2026, the largest Ceribell, Inc. (CBLL) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($110.7 million), BlackRock ($37.7 million), Vanguard Capital Management LLC ($22.0 million), Franklin Resources ($17.9 million), BNY Mellon ($17.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CBLL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ceribell, Inc. (CBLL) reported revenue of $89.1 million (up 36.1% from FY2024) and a net loss of $53.4 million. Diluted EPS was -$1.46. The figures come from the XBRL data in the 10-K.
What did CBLL report in its latest 8-K?
Ceribell, Inc. (CBLL) filed an 8-K on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended June 30, 2026 results announced August 10, 2026.
What are the latest CBLL SEC filings?
Ceribell, Inc. (CBLL) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on October 2, 2026.
What is CBLL's SEC CIK number?
Ceribell, Inc. (CBLL)'s SEC Central Index Key (CIK) is 1861107. EDGAR lists every CBLL filing under that number.
Ask anything about CBLL
The research agent reads CBLL's filings, financials, insider trades and 13F holders, then answers with sources.